Related references
Note: Only part of the references are listed.PSMA-Targeting Imaging and Theranostic Agents-Current Status and Future Perspective
Sashi Debnath et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2022)
Cancer-cell-derived GABA promotes beta-catenin-mediated tumour growth and immunosuppression
De Huang et al.
NATURE CELL BIOLOGY (2022)
EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer. Part II-2020 Update: Treatment of Relapsing and Metastatic Prostate Cancer
Philip Cornford et al.
EUROPEAN UROLOGY (2021)
Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
Hyuna Sung et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2021)
B cell-derived GABA elicits IL-10+ macrophages to limit anti-tumour immunity
Baihao Zhang et al.
NATURE (2021)
Prognostic role of proliferating CD8+ cytotoxic Tcells in human cancers
Niclas C. Blessin et al.
CELLULAR ONCOLOGY (2021)
Prevalence of proliferating CD8+ cells in normal lymphatic tissues, inflammation and cancer
Niclas C. Blessin et al.
Aging-US (2021)
Prevalence of CD8+ cytotoxic lymphocytes in human neoplasms
Niclas C. Blessin et al.
CELLULAR ONCOLOGY (2020)
Prostate cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
C. Parker et al.
ANNALS OF ONCOLOGY (2020)
Characterization of Glycolysis-Associated Molecules in the Tumor Microenvironment Revealed by Pan-Cancer Tissues and Lung Cancer Single Cell Data
Jinfen Wei et al.
CANCERS (2020)
Therapy-induced lipid uptake and remodeling underpin ferroptosis hypersensitivity in prostate cancer
Kaylyn D. Tousignant et al.
CANCER & METABOLISM (2020)
The Landscape of Immune Cells Infiltrating in Prostate Cancer
Zhicong Wu et al.
FRONTIERS IN ONCOLOGY (2020)
Activation of MAPK Signaling by CXCR7 Leads to Enzalutamide Resistance in Prostate Cancer
Shangze Li et al.
CANCER RESEARCH (2019)
Prostate-specific membrane antigen cleavage of vitamin B9 stimulates oncogenic signaling through metabotropic glutamate receptors
Charalambos Kaittanis et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2018)
225Ac-PSMA-617 for PSMA-Targeted a-Radiation Therapy of Metastatic Castration-Resistant Prostate Cancer
Clemens Kratochwil et al.
JOURNAL OF NUCLEAR MEDICINE (2016)
Divergent clonal evolution of castration-resistant neuroendocrine prostate cancer
Himisha Beltran et al.
NATURE MEDICINE (2016)
Acquired resistance to the second-generation androgen receptor antagonist enzalutamide in castration-resistant prostate cancer
Steven Kregel et al.
ONCOTARGET (2016)
A Phase I/II Study for Analytic Validation of 89Zr-J591 ImmunoPET as a Molecular Imaging Agent for Metastatic Prostate Cancer
Neeta Pandit-Taskar et al.
CLINICAL CANCER RESEARCH (2015)
limma powers differential expression analyses for RNA-sequencing and microarray studies
Matthew E. Ritchie et al.
NUCLEIC ACIDS RESEARCH (2015)
Androgen Receptor Splice Variants Determine Taxane Sensitivity in Prostate Cancer
Maria Thadani-Mulero et al.
CANCER RESEARCH (2014)
AR-V7 and Resistance to Enzalutamide and Abiraterone in Prostate Cancer
Emmanuel S. Antonarakis et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Enzalutamide in Metastatic Prostate Cancer before Chemotherapy REPLY
Tomasz M. Beer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
A Fluorescence-Coupled Assay for Gamma Aminobutyric Acid (GABA) Reveals Metabolic Stress-Induced Modulation of GABA Content in Neuroendocrine Cancer
Joseph E. Ippolito et al.
PLOS ONE (2014)
The role of the SHH gene in prostate cancer cell resistance to paclitaxel
Malgorzata Statkiewicz et al.
PROSTATE (2014)
Enzalutamide in Metastatic Prostate Cancer before Chemotherapy
T. M. Beer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Glucocorticoid Receptor Confers Resistance to Antiandrogens by Bypassing Androgen Receptor Blockade
Vivek K. Arora et al.
CELL (2013)
Enzalutamide for Treatment of Patients with Metastatic Castration-Resistant Prostate Cancer Who Have Previously Received Docetaxel: U.S. Food and Drug Administration Drug Approval Summary
Yangmin M. Ning et al.
CLINICAL CANCER RESEARCH (2013)
An F876L Mutation in Androgen Receptor Confers Genetic and Phenotypic Resistance to MDV3100 (Enzalutamide)
Manav Korpal et al.
CANCER DISCOVERY (2013)
Suppression of Acquired Docetaxel Resistance in Prostate Cancer through Depletion of Notch- and Hedgehog-Dependent Tumor-Initiating Cells
Josep Domingo-Domenech et al.
CANCER CELL (2012)
Identification of Docetaxel Resistance Genes in Castration-Resistant Prostate Cancer
Mercedes Marin-Aguilera et al.
MOLECULAR CANCER THERAPEUTICS (2012)
clusterProfiler: an R Package for Comparing Biological Themes Among Gene Clusters
Guangchuang Yu et al.
OMICS-A JOURNAL OF INTEGRATIVE BIOLOGY (2012)
Characterisation and manipulation of docetaxel resistant prostate cancer cell lines
Amanda J. O'Neill et al.
MOLECULAR CANCER (2011)
Metabolomic Profiling Reveals a Role for Androgen in Activating Amino Acid Metabolism and Methylation in Prostate Cancer Cells
Nagireddy Putluri et al.
PLOS ONE (2011)
GAD1 is a biomarker for benign and malignant prostatic tissue
Sara Jonmarker Jaraj et al.
SCANDINAVIAN JOURNAL OF UROLOGY AND NEPHROLOGY (2011)
Class III β-Tubulin Expression Predicts Prostate Tumor Aggressiveness and Patient Response to Docetaxel-Based Chemotherapy
Guillaume Ploussard et al.
CANCER RESEARCH (2010)
Guidelines for the management of castrate-resistant prostate cancer
Fred Saad et al.
CUAJ-CANADIAN UROLOGICAL ASSOCIATION JOURNAL (2010)
Inhibition of the Androgen Receptor as a Novel Mechanism of Taxol Chemotherapy in Prostate Cancer
Lu Gan et al.
CANCER RESEARCH (2009)
Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression
Arun Sreekumar et al.
NATURE (2009)
The Prostate Specific Membrane Antigen Regulates the Expression of IL-6 and CCL5 in Prostate Tumour Cells by Activating the MAPK Pathways
Marco Colombatti et al.
PLOS ONE (2009)
Proteomic Interrogation of Androgen Action in Prostate Cancer Cells Reveals Roles of Aminoacyl tRNA Synthetases
Adaikkalam Vellaichamy et al.
PLOS ONE (2009)
Development of a Second-Generation Antiandrogen for Treatment of Advanced Prostate Cancer
Chris Tran et al.
SCIENCE (2009)
Androgen deprivation therapy: progress in understanding mechanisms of resistance and optimizing androgen depletion
William P. Harris et al.
NATURE CLINICAL PRACTICE UROLOGY (2009)
Moderate Expression of Prostate-Specific Membrane Antigen, a Tissue Differentiation Antigen and Folate Hydrolase, Facilitates Prostate Carcinogenesis
Veronica Yao et al.
CANCER RESEARCH (2008)
Splicing of a novel androgen receptor exon generates a constitutively active androgen receptor that mediates prostate cancer therapy resistance
Scott M. Dehm et al.
CANCER RESEARCH (2008)
Mitotic catastrophe and apoptosis induced by Docetaxel in hormone-refractory prostate cancer cells
Francesco Fabbri et al.
JOURNAL OF CELLULAR PHYSIOLOGY (2008)
Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer
DP Petrylak et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer
IF Tannock et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Share Paper
